We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Advanced Medical Solutions Group Plc | LSE:AMS | London | Ordinary Share | GB0004536594 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
5.80 | 3.05% | 195.80 | 196.00 | 197.00 | 196.40 | 189.20 | 190.20 | 296,039 | 11:44:14 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Plastics,resins,elastomers | 124.33M | 20.41M | 0.0939 | 20.89 | 426.17M |
Date | Subject | Author | Discuss |
---|---|---|---|
27/1/2017 17:13 | Candlesticks charts suggest 'hammer' formed, which is positive after downtrend | wetdream | |
27/1/2017 16:27 | I see little downside at these levels. It's come back with all of the pharmas. last trading statement was the clue that AMS will benefit more from exchange rates this year than last because of their hedging policy. | zipstuck | |
25/1/2017 14:30 | A spirited discourse; In the old day's new products drove value. Now USA carrying the mantle. something has slowed down somewhere. | norbus | |
24/1/2017 20:55 | No problem. I enjoy hearing an alternative viewpoint also. I don't slavishly follow PEG ratios but they give me an idea whether I'm overpaying for growth. Totally useless for small cap stocks just emerging into profitability of course (or just at the start of a period of accelerating growth) - my main hunting ground. | hydrus | |
24/1/2017 20:38 | Numbers can be erroneous, H. I use TD Direct information. I cannot understand PEG - glamour ratio :-) I think german success is the important issue. Just realised, I thought this a long time ago! Last increased in Feb. 16 at 160p. Ambivalent, apad ps Thanks for the viewpoint. | apad | |
24/1/2017 20:16 | AMS Free Cash Flow yield: 4.46% ROCE: 29% Quick Ratio: 4.4 Not wildly overpriced based on my numbers, H. apad | apad | |
24/1/2017 20:02 | It's been wildly overpriced for some time so a correction to be expected. Still very expensive. | hydrus | |
19/1/2017 10:49 | Currency and EU sensitivity could be dictating the values. | norbus | |
16/12/2016 15:26 | Interesting pattern of buying. | small crow | |
15/12/2016 13:37 | Good solid trading statement today IMHO | dealit | |
28/10/2016 12:19 | The last set of interims were good but in my view probably put the share price ahead of where it should have been. So I feel the recent weakness to be about removing the froth and returning the price to a more realistic value for the growth potential. Having said that, AMS' share price has tended to lurch up and down from time to time but this feels a little more like a return to its historic trend. 200p might be about right for now. | skirbell | |
26/10/2016 06:18 | Thanks cynic. Difficult to know but I agree with all your possibles. Still holding strong, may even buy. | sir real | |
25/10/2016 21:44 | Something smells no reason for the price to drop, unless MM,s have no stock and dropped the bid by 10% from a high of £2,35 to hoover up the 10% stop loss idiots. Lots of buys after hours for the last couple of days, filling an order perhaps? or could be a takeover bid for the company coming? which wouldn't surprise me after the interim results. | cynic1 | |
25/10/2016 17:56 | Not aware of anything, but a lot of big pharma are reporting, GSK tomorrow. Still holding. | whitebicycle | |
25/10/2016 15:43 | Anyone care to comment on the recent sudden dip? | sir real | |
14/9/2016 10:34 | I'm in a similar dilemma with 32Red, currently sitting on a p/e north of 100! I'm holding out for the minute. | mrchriss | |
14/9/2016 10:04 | this was developed by Evans for J&J | norbus | |
14/9/2016 09:32 | I'd agree that this must be on a few acquisition radars. But how much would any company be prepared to pay for AMS? Even an offer at a 20% increase to the current share price could be seen as a hefty premium to be paying for the company. It might be enough to disuade a potential suitor at least. | skirbell | |
14/9/2016 08:45 | "The other option is the prospect of AMS being taken out. That would solve the dilemma!" It's hard to believe the likes of J&J aren't having a look. | small crow | |
14/9/2016 08:10 | That is the dilemma. Excellent results with a good outlook. Free cash flow and cash in the bank. Exactly what an investor should be looking for. But, even taking into account the cash and assuming a further 10 to 15% growth in H2, the PE is still north of 25. So you have to question how much more upside there is from here at this time. It's hard to argue that the share is currently cheap. An acquisition may ease the valuation although I didn't see anything about an actual opportunity, rather just looking for one (barring the aborted acquisition that makes up the exceptional item). The other option is the prospect of AMS being taken out. That would solve the dilemma! But I'm thinking it is probably time to take another tranche of profits off of the table. | skirbell | |
14/9/2016 06:19 | Good revenue growth but this is on a PE of 30 with 10% EPS growth - caution needed | hydrus | |
14/9/2016 06:10 | excellent results | norbus | |
13/9/2016 19:26 | Interims in the morning. | whitebicycle | |
09/9/2016 07:24 | Always the same - drop at open and then climb back to (usually) positive territory. Long may it continue. | small crow |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions